BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04592874 (AL002 in Alzheimer's Disease): BVCT ex-ante prediction vs. reported outcome

On 6 Aug 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 25 Nov 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT04592874
Acronym
INVOKE-2
Drug Name
AL002
Drug MoA
anti-TREM2 mAb activator
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Alzheimer's Disease
Human Patients
381
Sponsor
Alector / AbbVie
Phase
Phase 2

Prediction of , index 580

Prospective Prediction
Prediction Index
580
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit inferior to lecanemab)
Technical Prediction
FAILURE (statistically insignificant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
111 days in advance
Readout Data Interpretation
AL002 failed to meet primary efficacy endpoints CDR-SB
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Phase
Phase 2
Status
Completed
Enrollment
356
Lead sponsor
Alector Inc.
Conditions
Alzheimer Disease
Interventions
DRUG: AL002; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2021-01-22
Primary completion
2024-08-19
Completion
2024-09-12
Results first posted
2025-10-29
Primary outcomes
  • Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score (Study completion up to 96 weeks)

NCT04592874 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials